Abstract
HER2 and CDK4/6 are undoubted two most important biological targets for breast cancer. Anti-HER2 treatments enhance objective response and progression-free survival/disease-free survival as well as overall survival. Three CDK4/6 inhibitors consistently improve objective response and progression-free survival; however, overall survival data are waited. Optimization of chemotherapy and endocrine strategies remains an unmet need. Check point inhibitor-based immunotherapy combined with chemotherapy is a promising field, especially for triple-negative breast cancer.
Keywords:
ADC; Breast cancer; CDK4/6 inhibitors; Fulvestrant; Nab-paclitaxel; PARP inhibitors; PD1 and PD-L1 antibodies; SERD.
MeSH terms
-
Antibodies, Monoclonal / therapeutic use
-
Antineoplastic Agents, Hormonal / therapeutic use
-
Antineoplastic Agents, Immunological / therapeutic use
-
Breast Neoplasms / drug therapy
-
Breast Neoplasms / therapy*
-
Clinical Trials as Topic
-
Drug Carriers
-
Estradiol / analogs & derivatives
-
Estradiol / therapeutic use
-
Female
-
Fulvestrant
-
Humans
-
Immunoconjugates / therapeutic use
-
Immunotherapy / trends
-
Immunotherapy, Adoptive
-
Molecular Targeted Therapy / trends
-
Multicenter Studies as Topic
-
Neoplasm Proteins / antagonists & inhibitors
-
Piperazines / therapeutic use
-
Poly(ADP-ribose) Polymerase Inhibitors / therapeutic use
-
Protein Kinase Inhibitors / therapeutic use
-
Pyridines / therapeutic use
-
Therapies, Investigational*
-
Tubulin Modulators / pharmacology
Substances
-
Antibodies, Monoclonal
-
Antineoplastic Agents, Hormonal
-
Antineoplastic Agents, Immunological
-
Drug Carriers
-
Immunoconjugates
-
Neoplasm Proteins
-
Piperazines
-
Poly(ADP-ribose) Polymerase Inhibitors
-
Protein Kinase Inhibitors
-
Pyridines
-
Tubulin Modulators
-
Fulvestrant
-
Estradiol
-
palbociclib